Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CPA1 | P15085 | 7/20 | 0.49 |
| ▸ | CPA3 | P15088 | 3/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.49 |
| ▸ | CPB1 | P15086 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700981 | 0.85 | CHRM1 (0.46) | CYP1A2UBE2NCHRM1 | |
| SCHEMBL7322967 | 0.84 | CYP1A2 (0.66) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7322955 | 0.84 | CYP1A2 (0.66) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7322961 | 0.84 | CYP1A2 (0.66) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7331929 | 0.80 | CYP1A2 (0.59) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7325560 | 0.80 | CYP1A2 (0.59) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7331926 | 0.80 | CYP1A2 (0.59) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7348130 | 0.78 | CYP1A2 (0.61) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7348126 | 0.78 | CYP1A2 (0.61) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL7325595 | 0.78 | CYP1A2 (0.66) | CYP1A2CPA1CPA3FOLH1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192780-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2004-09-30 | — | — | US | disclosed |
| US-20030236201-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2003-12-25 | — | — | US | disclosed |
| US-6403648-B2 | RENIN INHIBITOR | G. D. SEARLE & CO. | 2002-06-11 | — | — | US | disclosed |
| US-20020010214-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2002-01-24 | — | — | US | disclosed |
| US-6291529-B1 | RENIN INHIBITORS; TREATING GLAUCOMA | G. D. SEARLE & CO. | 2001-09-18 | — | — | US | disclosed |
| US-20010011101-A1 | Alkylaminoalkyl-sulfonyl-terminated Beta-alanineamide amino-diol compounds for treatment of hypertension | HANSON GUNNAR J (US) | 2001-08-02 | — | — | US | disclosed |
| US-5968984-A | Alkylaminoalkyl-sulfonyl-terminated β-alanineamide amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5488066-A | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing cycloalkyl-alanine amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5488067-A | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1996-01-30 | — | — | US | disclosed |
| US-5432201-A | Alkylaminoalkyl-sulfonyl-terminated β-alanineamide amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1995-07-11 | — | — | US | disclosed |
| US-5416119-A | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing cycloalkyl-alanine amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1995-05-16 | — | — | US | disclosed |
| US-5414018-A | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1995-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011101-A1 | Alkylaminoalkyl-sulfonyl-terminated Beta-alanineamide amino-diol compounds for treatment of hypertension | REN, AGTR1, AGT | CYP1A2 702/4885CPA1 317/4885CPA3 1529/4885 |
| US-20030236201-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | CYP1A2 1242/4885CPA1 2258/4885CPA3 3218/4885 |
| US-20040192780-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | CYP1A2 1242/4885CPA1 2258/4885CPA3 3218/4885 |
| US-20020010214-A1 | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension | REN, AGTR1, AGTR2 | CYP1A2 1242/4885CPA1 2258/4885CPA3 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.